We use cookies to improve your experience on our site and to analyze traffic. By clicking "Accept", you consent to our use of cookies. Learn more.
Blog
The latest from Nova In Silico: research updates, press releases, and industry perspectives.
A model is a representation of natural phenomena by means of physical or computer processes, logical relations or mathematical formulas. The representation can be essentially graphic or only discursiv…
A real-world randomized clinical trial (RCT) is grounded in sampling theory and follows a rigorous methodology. In practice, this method involves recruiting eligible patients from participating sites …
Authors: Prof. Jean-Pierre Boissel, Claudio Monteiro, Emmanuel Pham, François-Henri Boissel In silico clinical trials (or “ISCTs”), as with any new approach, has to battle against persistent myths…
Download the Press Release Quantitative Systems Pharmacology (QSP) mo…
Download the Press Release / <a style="font-size: 16px; color: #3f…
Personalized medicine is more than matching a drug to an individual. It also means getting the dose right. Yet dose optimization, as a strategy to improve patient care, is <a href="https://www.researc…
On November 9, FDA held a workshop<span style="font-wei…
If you’re into technology, you’ve probably heard the term “digital twins”. It originated in space engineering - at NASA - in the 2010s. Since then, groups from almost every industry have appropriated …
In silico modeling is emerging as an important partial alternative to animal testing. Animals, in particular genetically-engineered mice, have long been used to test medicines before they go into hu…
When embarking on a new R D program, drug developers face a strategic and moral imperative to assemble the best, most relevant available data and insights. The explosion in scientific literature and i…
In silico trials are computer-based simulations of how a drug or disease impacts physiological and clinical outcomes. They can help improve and shorten conventional in-person trials, by testing hypoth…
Faster drug approvals based on less evidence mean new tools are needed to track cost-effectiveness. As regulators approve more drugs faster , health technology a…
2021 was a standout year for drug development. The <a href="https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021" targ…
A new generation of clinical research is arising, thanks to a profusion of health data and data-powered technologies such as in silico modeling. More data, by itself, does not guarantee better results…
Control arms are key to reliably determining whether a new treatment works better than what already exists. The data they generate – from trial patients who receive a placebo, the standard of care (SO…
How two distinct, yet complementary approaches could revolutionize R D Mechanistic modeling and artificial intelligence (AI) are both transforming medicine. AI is being increasingly applied to drug di…
As technology spreads across healthcare, the trust question becomes more urgent. Should we trust what a digital health app tells us? Can we rely on a diagnosis provided by an algorithm? Can drug devel…
It’s a red-hot question: how to bridge the gap between available and desired levels of evidence for a drug’s safety and efficacy? <a href="https://www.fda.gov/news-events/press-announcements/fda-grant…
No clinical trial is perfect. The gold-standard randomized controlled trial does a good job of trying to be, but we know its flaws: selection isn’t truly random, conditions often don’t reflect patient…
Covid and Computers: is it time to embrace trial simulations? We are doing things differently now. For many of us, life has shifted online – shopping, doctor’s v…